As we mark the end of Breast Cancer Awareness Month, we reflect on an extraordinary year of progress in women’s health innovation and impact investing. 2025 has been defined by scalable growth, transformative partnerships, and the continued mission to build equitable access to early cancer detection around the world.
From redefining screening access to unlocking scalable public-private partnerships, UE LifeSciences continues to prove that impact and sustainability can coexist.
Global News
Distribution Collaboration
This August, UE LifeSciences signed an exclusive distribution partnership for licensing and marketing with Molbio Diagnostics to expand iBreastExam in India, the Middle East, Africa, CIS countries and Indonesia, Philippines and Vietnam (in collaboration with Wellesta). This collaboration will ensure that iBreastExam’s reach expands to new regions, determined by a focused lens on impact.
Fire4Fire: Responsible AI/ML Initiative for Women's Health
This initiative focuses on building commercial grade tech as an aid to enhance human decision making in the early detection and treatment of leading cancers in women. The initiative leverages machine vision, conversational AI, and other tools for interactive user support, cancer risk assessment, and to better equip the human stakeholders in the care journey to improve skills and knowledge. UE LifeSciences is committed to addressing AI’s ethical implications, prioritizing safety, transparency, and continuous performance monitoring to ensure benefits outweigh risks for patients, clinicians, and health systems. AI applications for early cancer detection will undergo rigorous testing and independent validations to ensure clinical reliability.
Japan Patent
UE LifeSciences is proud to announce that iBreastExam has received patent approval from the Japan Patent Office (JPO), marking a significant step in our global intellectual property strategy. This achievement strengthens our position in one of the world’s leading medical technology markets. With Japan’s strong commitment to healthcare innovation and quality assurance, this patent unlocks new opportunities for commercial partnerships, clinical collaborations, and regulatory alignment across the Asia-Pacific region.
Region: South Asia
Rotary MOU
UE LifeSciences, a pioneer in innovative breast cancer screening technology, has signed of a Memorandum of Understanding (MoU) with Rotary Club of Mumbai Nova and Rotary District 3141, one of the top districts in the Rotary world, to launch breast cancer screening initiatives.
Effective July 1, 2025, this transformative partnership aims to conduct 100,000 breast cancer screenings for underserved women across Mumbai, breaking down barriers to critical healthcare access and ensuring early detection for those facing challenges in accessing vital medical services. Building on a successful collaboration between UE LifeSciences and Rotary that has already provided early breast cancer detection to over 50,000 women, this expanded programme will significantly amplify these efforts, bringing accessible and affordable gold-standard care directly to communities that need it most.
Swasth Mahila Swasth Bharat
In conjunction with the YouWeCan Foundation, the Swasth Mahila Swasth Bharat initiative has completed 1.5L scans and is predicted to complete another 60,000 scans.
Swasth Mahila Swasth Goa
The initiative hit a major milestone this year with 170,000+ total screenings and local government support for statewide expansion and an MOU renewal is in process. This program remains a global model for sustainable, community-driven cancer screening.
Clinical Studies
TATA Memorial Hospital
The ongoing clinical study at Tata Memorial Hospital evaluating iBreastExam’s accuracy and clinical performance continues to make strong progress and is expected to be published soon in a peer-reviewed medical journal. This landmark research marks a significant milestone in validating iBreastExam as an accessible, technology-driven tool for breast health screening in diverse population settings. Early findings are promising and reinforce the device’s potential to transform community-level breast cancer detection through affordable, radiation-free innovation. With publication on the horizon, we anticipate this study to further strengthen clinical confidence and open new pathways for large-scale adoption across India and emerging markets.
AIIMS Rishikesh
The AIIMS Rishikesh clinical study evaluating iBreastExam’s effectiveness in early breast lesion detection is nearing completion and soon to be published. Conducted by one of India’s leading academic medical institutions, this study underscores iBreastExam’s strong clinical validation and its role in improving breast cancer screening accessibility. Preliminary outcomes suggest high concordance with standard diagnostic methods, reinforcing the technology’s value in both urban and rural healthcare environments. The forthcoming publication is expected to further build scientific credibility and accelerate adoption through public health programs and institutional collaborations.
Region: South East Asia
Duopharma CME Central (June 2025)
Duopharma, in collaboration with the Malaysian Medical Association (MMA), organized a CME session attended by around 200 doctors and pharmacists.
As part of the event, Duopharma set up an iBreastExam booth to showcase the device’s capabilities in early breast health screening. Attendees had the opportunity to learn about the technology, observe live demonstrations, and understand its role in improving early detection and accessibility of breast cancer screening.
Fruitful Collaboration with Duopharma, PERKESO & Malaysian Red Crescent (June 2025)
The discussion, joined by Mr. Danial Iskandar Abdul Rahman, Secretary General of MRCS, focused on strengthening partnerships to make early detection more accessible to communities nationwide.
Region: North America
Find It Early Act: Women’s Health Capitol Hill Day in Washington, D.C., hosted by BCEDC and WHA
The Coalition is mobilizing advocates, clinicians, and lawmakers to create a consistent national framework for coverage of supplemental imaging, closing critical gaps in early breast cancer detection. Once passed, the Find It Early Act will remove financial barriers to screening, improve early detection for women with dense breasts, and reduce late-stage diagnoses—driving both health equity and long-term cost savings.
This legislation directly supports our mission and market expansion—establishing reimbursement clarity and coverage parity for innovative femtech solutions like iBreastExam and Selfi, positioning UE LifeSciences to scale nationwide across provider networks, payers, and employer health programs. We see policy alignment as a key growth catalyst accelerating adoption of accessible, AI-enabled breast health technologies globally.
Raising Health Partners Breast camp using iBreastExam
We were proud to partner with Raising Health Partners at the Brooklyn Health Fair, providing iBreastExam screenings to women in underserved neighborhoods. With the support of the ACC Asian Community Center, who kindly hosts and supports community-based early detection. Events like these showcase how technology and partnerships can scale access to preventive care and deliver measurable impact for women’s health globally.
UE LifeSciences at Womens Health Innovation Summit 2025, Boston
Our Vice President Partnerships, Smita Asrani had attended the Womens Health Innovation Summit in Boston to highlight the fastest-growing global markets in women’s health and explore the regional drivers of demand, from shifting demographics to evolving healthcare policies. During her panel discussion, she discussed strategies for scaling women’s health solutions internationally, including navigating regulatory landscapes, reimbursement pathways, and local partnerships.
Recognitions and Thought Leadership
Global Stage, Global Impact
Media Spotlight: “Molecules of Hope”
Our inclusion in EdStead’s “Molecules of Hope” (on JioHotstar) series brought a human face to innovation—telling the story of the many hands that enable early detection. From community leaders, ministers, techpreneurs and sons, each story reinforces the measurable social return our technologies generate.
Looking Ahead: Investing in the Future of Women’s Health
As we close in on year-end, our focus remains on scaling affordability and accessibility—with new funding partnerships, deeper penetration into private health ecosystems, and the rollout of next-generation innovations aimed at bridging the gap between early detection and timely treatment.
Every milestone this year reinforces a simple truth: investing in women’s health is investing in collective progress.
Here’s to empowering every woman, everywhere—with access, equity, and early detection.
Onwards and upwards!
— The UE LifeSciences Team